Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Operating Expenses: 2011-2025

Historic Operating Expenses for Adma Biologics (ADMA) over the last 12 years, with Sep 2025 value amounting to $24.6 million.

  • Adma Biologics' Operating Expenses rose 22.94% to $24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.3 million, marking a year-over-year increase of 38.47%. This contributed to the annual value of $80.6 million for FY2024, which is 19.70% up from last year.
  • According to the latest figures from Q3 2025, Adma Biologics' Operating Expenses is $24.6 million, which was up 0.76% from $24.4 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Operating Expenses ranged from a high of $26.2 million in Q1 2025 and a low of $13.4 million during Q1 2021.
  • Over the past 3 years, Adma Biologics' median Operating Expenses value was $18.3 million (recorded in 2024), while the average stood at $20.3 million.
  • Data for Adma Biologics' Operating Expenses shows a peak YoY increase of 155.46% (in 2021) and a maximum YoY decrease of 50.16% (in 2021) over the last 5 years.
  • Adma Biologics' Operating Expenses (Quarterly) stood at $16.7 million in 2021, then rose by 21.15% to $20.2 million in 2022, then fell by 16.72% to $16.9 million in 2023, then spiked by 48.40% to $25.0 million in 2024, then climbed by 22.94% to $24.6 million in 2025.
  • Its Operating Expenses stands at $24.6 million for Q3 2025, versus $24.4 million for Q2 2025 and $26.2 million for Q1 2025.